表观遗传学
生物
结直肠癌
癌症
生物信息学
遗传学
癌症研究
肿瘤科
计算生物学
基因
医学
作者
Mahsa Akbari Oryani,Afsaneh Tavasoli,Mohammad Amin Ghalavand,Rahele Zokaei Ashtiani,Alisam Rezaee,Rasadokht Mahmoudi,Hossein Golvari,Soroor Owrangi,Mehdi Soleymani-Goloujeh
出处
期刊:Epigenomics
[Future Medicine]
日期:2022-06-01
卷期号:14 (11): 683-697
被引量:3
标识
DOI:10.2217/epi-2022-0067
摘要
It is estimated that colorectal cancer (CRC) is the leading cause of cancer-related death around the globe. 'Epigenetics' refers to changes in the chromosome rather than the DNA sequence, which may be transmitted down to daughter cells. Epigenetics is an essential part of controlling the development and variation of a single cell. ncRNAs have a role in epigenetic regulation in CRC, which will be discussed in this review in the context of DNA methylation and histone modifications. A greater survival rate for CRC patients might be achieved by addressing epigenetic mediators, as the authors show. In this review, they aim to thoroughly examine the role of epigenetics in the prognosis, diagnosis and treatment of CRC.Colorectal cancer (CRC) is one of the leading causes of cancer-related death around the world. There are different methods and strategies to diagnose and treat CRC, but there are some hurdles in the prediction and early diagnosis of this disease. Epigenetics is considered to be alterations occurring in the chromosome rather than in the DNA sequence without changing its biochemical identity. Nowadays, it appears that epigenetics plays a critical role in overcoming some obstacles in the diagnosis and treatment of CRC. Targeting epigenetic mediators may provide a higher survival rate for CRC patients. In this review, the authors predict that combinational therapy (including epigenetics) may be one of the best options for most cancers, including CRC.
科研通智能强力驱动
Strongly Powered by AbleSci AI